Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastroenterol. Nov 7, 2026; 32(41): 123866
Published online Nov 7, 2026. doi: 10.3748/wjg.123866
Published online Nov 7, 2026. doi: 10.3748/wjg.123866
Magnesium isoglycyrrhizinate in perioperative hepatic function protection: Insights from a clinical pharmacy perspective
Nan-Lan Ding, Feng Zhang, Fu-Shan Tang, Department of Clinical Pharmacy, Key Laboratory of Basic Pharmacology of Guizhou Province and School of Pharmacy, Zunyi Medical University, Zunyi 563006, Guizhou Province, China
Author contributions: Ding NL drafted and revised the manuscript; Zhang F provided discussion and literature support; Tang FS contributed to idea generation, revised the manuscript, and provided supervision; all authors reviewed and approved the final manuscript.
AI contribution statement: Portions of this manuscript were edited using AI tools solely for language refinement.
Conflict-of-interest statement: The authors declare no conflicts of interest. No financial support, commercial funding, consultancy fees, stock ownership, patents or other economic interests related to this work have been received by any author that could bias the research outcomes.
Corresponding author: Fu-Shan Tang, PhD, Professor, Department of Clinical Pharmacy, Key Laboratory of Basic Pharmacology of Guizhou Province and School of Pharmacy, Zunyi Medical University, No. 6 Xuefu West Road, Xinpu New District, Zunyi 563006, Guizhou Province, China. fstang@vip.163.com
Received: June 1, 2026
Revised: July 19, 2026
Accepted: July 27, 2026
Published online: November 7, 2026
Processing time: 107 Days and 7.1 Hours
Revised: July 19, 2026
Accepted: July 27, 2026
Published online: November 7, 2026
Processing time: 107 Days and 7.1 Hours
Core Tip
Core Tip: This letter to the editor reviews a recent study demonstrating that perioperative administration of magnesium isoglycyrrhizinate (MgIG) can mitigate postoperative liver injury and accelerate hepatic function recovery following hepatectomy. We emphasize the necessity of implementing measures, including risk-stratified patient selection, safety monitoring, pharmacotherapy management, mechanism investigation, and pharmacoeconomic evaluation, to standardize and optimize the clinical application of MgIG during hepatectomy.